| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tetracaine HCl: Essential Information
High-Purity Pharmaceutical Anesthetic HCl Powder - CAS 136-47-0: Tetracaine & Lidocaine
Lidocaine hydrochloride undergoes rapid metabolism in the liver, with both metabolites and unchanged drug excreted through the kidneys. The biotransformation processes include oxidative N-dealkylation, ring hydroxylation, amide linkage cleavage, and conjugation. N-dealkylation, a primary pathway, produces monoethylglycinexylidide and glycinexylidide metabolites, which exhibit similar but less potent pharmacological/toxicological effects compared to Lidocaine hydrochloride. Approximately 90% of administered Lidocaine hydrochloride is excreted as various metabolites, while less than 10% is excreted unchanged. The major urinary metabolite is a conjugate of 4-hydroxy-2,6-dimethylaniline.
Lidocaine HCl: An Advanced Amide Local Anesthetic.
With increasing doses, both efficacy and toxicity rise, exhibiting anti-convulsive effects at sub-toxic plasma concentrations.
Blood concentrations exceeding 5μg ? ml-1 may induce convulsions.
){kind=link}